全文获取类型
收费全文 | 27445篇 |
免费 | 2643篇 |
国内免费 | 32篇 |
专业分类
耳鼻咽喉 | 244篇 |
儿科学 | 833篇 |
妇产科学 | 629篇 |
基础医学 | 3685篇 |
口腔科学 | 625篇 |
临床医学 | 3101篇 |
内科学 | 5576篇 |
皮肤病学 | 379篇 |
神经病学 | 2856篇 |
特种医学 | 978篇 |
外科学 | 3518篇 |
综合类 | 633篇 |
一般理论 | 18篇 |
预防医学 | 2848篇 |
眼科学 | 694篇 |
药学 | 2215篇 |
1篇 | |
中国医学 | 30篇 |
肿瘤学 | 1257篇 |
出版年
2021年 | 386篇 |
2020年 | 220篇 |
2019年 | 389篇 |
2018年 | 442篇 |
2017年 | 364篇 |
2016年 | 372篇 |
2015年 | 407篇 |
2014年 | 577篇 |
2013年 | 858篇 |
2012年 | 1256篇 |
2011年 | 1291篇 |
2010年 | 736篇 |
2009年 | 609篇 |
2008年 | 1115篇 |
2007年 | 1272篇 |
2006年 | 1193篇 |
2005年 | 1261篇 |
2004年 | 1123篇 |
2003年 | 1167篇 |
2002年 | 1054篇 |
2001年 | 780篇 |
2000年 | 798篇 |
1999年 | 679篇 |
1998年 | 312篇 |
1997年 | 261篇 |
1996年 | 226篇 |
1995年 | 278篇 |
1994年 | 245篇 |
1992年 | 582篇 |
1991年 | 540篇 |
1990年 | 521篇 |
1989年 | 519篇 |
1988年 | 473篇 |
1987年 | 475篇 |
1986年 | 420篇 |
1985年 | 489篇 |
1984年 | 416篇 |
1983年 | 326篇 |
1982年 | 319篇 |
1981年 | 252篇 |
1980年 | 254篇 |
1979年 | 388篇 |
1978年 | 322篇 |
1977年 | 236篇 |
1976年 | 257篇 |
1975年 | 236篇 |
1974年 | 299篇 |
1973年 | 316篇 |
1972年 | 246篇 |
1971年 | 234篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
1.
2.
3.
Oliver Sartor MD Daniel Heinrich MD Neil Mariados MD Maria José Méndez Vidal MD Daniel Keizman MD Camilla Thellenberg Karlsson MD Avivit Peer MD Giuseppe Procopio MD Stephen J. Frank MD Kalevi Pulkkanen MD Eli Rosenbaum MD Stefano Severi MD José Trigo MD Lucia Trandafir MD Volker Wagner MD Rui Li MS Luke T. Nordquist MD 《The Prostate》2019,79(14):1683-1691
4.
5.
J.L. Bernat A.M. D'Alessandro F.K. Port T.P. Bleck S.O. Heard J. Medina S.H. Rosenbaum M.A. DeVita R.S. Gaston R.M. Merion M.L. Barr W.H. Marks H. Nathan K. O'Connor D.L. Rudow A.B. Leichtman P. Schwab N.L. Ascher R.A. Metzger V. Mc Bride W. Graham D. Wagner J. Warren F.L. Delmonico 《American journal of transplantation》2006,6(2):281-291
A national conference on organ donation after cardiac death (DCD) was convened to expand the practice of DCD in the continuum of quality end-of-life care. This national conference affirmed the ethical propriety of DCD as not violating the dead donor rule. Further, by new developments not previously reported, the conference resolved controversy regarding the period of circulatory cessation that determines death and allows administration of pre-recovery pharmacologic agents, it established conditions of DCD eligibility, it presented current data regarding the successful transplantation of organs from DCD, it proposed a new framework of data reporting regarding ischemic events, it made specific recommendations to agencies and organizations to remove barriers to DCD, it brought guidance regarding organ allocation and the process of informed consent and it set an action plan to address media issues. When a consensual decision is made to withdraw life support by the attending physician and patient or by the attending physician and a family member or surrogate (particularly in an intensive care unit), a routine opportunity for DCD should be available to honor the deceased donor's wishes in every donor service area (DSA) of the United States. 相似文献
6.
Matthew S Lewis Paul Maruff Brendan S Silbert Lis A Evered David A Scott 《Archives of clinical neuropsychology》2006,21(5):421-427
The reliable change index (RCI) expresses change relative to its associated error, and is useful in the identification of post-operative cognitive dysfunction (POCD). This paper examines four common RCIs that each account for error in different ways. Three rules incorporate a constant correction for practice effects and are contrasted with the standard RCI that had no correction for practice. These rules are applied to 160 patients undergoing coronary artery bypass graft (CABG) surgery who completed neuropsychological assessments preoperatively and 1 week post-operatively using error and reliability data from a comparable healthy non-surgical control group. The rules all identify POCD in a similar proportion of patients, but the use of the within subject standard deviation, expressing the effects of random error, as an error estimate is a theoretically appropriate denominator when a constant error correction, removing the effects of systematic error, is deducted from the numerator in a RCI. 相似文献
7.
Improved graft survival for flow cytometry and antihuman globulin crossmatch-negative retransplant recipients 总被引:1,自引:0,他引:1
R H Kerman C T Van Buren R M Lewis V DeVera V Baghdahsarian K Gerolami B D Kahan 《Transplantation》1990,49(1):52-56
We compared our standard NIH (extended incubation) crossmatch (XM) with antihuman globulin (AHG) and flow cytometry XMs and correlated the results with rejection episodes and graft survivals. For 89 CsA-Pred, primary renal allograft recipients, AHG and/or FCXM results did not improve on the NIH-XM-negative (NEG) graft survival results, whether testing pretransplant or historical (Hx) sera. Similarly, there was no association of a positive (POS) AHG or FCXM with increased rejection episodes in these primary recipients. However, for retransplant (Re-Tx) recipients a neg AHG or FCXM did discriminate fewer rejections and an improved graft survival compared with the NIH-XM-neg. results. The overall one-year graft survival for the 47 Re-Tx recipients studied herein was 66% (based on a neg pre-Tx NIH-XM). Pre-Tx AHG-NEG, Re-Tx recipients displayed an improved graft survival compared with NIH-XM NEG recipients (77% vs. 66%, P less than 0.05) and with AHG-POS recipients (77% vs. 47%, P less than 0.05). Similarly, pre-Tx, FCXM-NEG, Re-Tx recipients displayed improved graft survivals compared with NIH-XM-NEG recipients (83% vs. 66%, P less than 0.05) and FCXM-POS recipients (83% vs. 48%, P less than 0.05). Re-Tx recipients displaying a POS AHG and/or FCXM experienced a significantly greater number of rejections than NEG-XM recipients (P less than 0.05, respectively). The AHG and FCXM results correlated with rejections and graft survivals whether testing pre-Tx or Hx high-PRA sera. Re-Tx recipients who were AHG-XM-NEG but FCXM-POS, experienced more rejection episodes than recipients who displayed a negative XM reactivity for both AHG and FCXM (P less than 0.02), but with no resulting differences in graft survival. HLA matching, pre-Tx blood transfusions and PRA did not impact on these crossmatch and graft survival results. Use of AHG and/or FCXMs for Re-Tx, but not primary, recipients should help to improve graft survival for these high-risk recipients. 相似文献
8.
Double-blind, placebo-controlled comparison of clonazepam and alprazolam for panic disorder 总被引:1,自引:0,他引:1
G E Tesar J F Rosenbaum M H Pollack M W Otto G S Sachs J B Herman L S Cohen S A Spier 《The Journal of clinical psychiatry》1991,52(2):69-76
To test the reported antipanic efficacy of clonazepam, the authors randomized 72 subjects with panic disorder to 6 weeks of treatment with either alprazolam, clonazepam, or placebo. Endpoint analysis demonstrated a significant beneficial effect of both active treatments, but not placebo treatment, on the frequency of panic attacks, overall phobia ratings, and the extent of disability. Comparison of the two active treatments revealed no significant differences and no consistent tendency for one agent to be favored over another, although power to detect small differences was limited. Sedation and ataxia were the most common side effects reported, but these effects were mild and transient and did not interfere with treatment outcome. The results of this double-blind, placebo-controlled trial are consistent with previous reports of clonazepam's antipanic efficacy. 相似文献
9.
The exact location of hemorrhage complicating anticoagulant therapy is sometimes difficult to establish. We present a case in which imaging with 99mTc-labeled red cells had a significant role in the diagnosis of soft-tissue bleeding in a paraplegic patient receiving long-term anticoagulation. 相似文献
10.
The Brief Symptom Inventory (BSI), a 53-item psychiatric symptom checklist, was administered to 57 alcoholic inpatients on days 2, 10, 18 and 26 of their 28-day stay in an alcoholism rehabilitation unit at a Veterans Administration hospital. The results of the test show a steady decline in the patients' psychiatric symptomatology from week 1 to week 4 with the most dramatic improvement evidenced between weeks 1 and 2. 相似文献